|
Vol. 12.12 – 28 March, 2023
|
|
|
|
|
|
Investigators identified circulating tumor cell biomarkers and effective combinations of tumor-initiating stem-like cell-specific, repurposed FDA-approved drugs. [Advanced Science]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Researchers reported that terminally exhausted (TTEX) cells actively participated in tumor progression by modulating CSCs. TTEX cells strongly correlated with elevated CSC frequency in poorly immune-infiltrated advanced human breast and ovarian carcinomas.
[Cancer Research]
|
|
|
|
|
Monodisperse hollow-structured MnO2 was successively modified with hyaluronic acid to enhance targeting CSCs with high CD44 expression levels.
[ACS Applied Materials & Interfaces]
|
|
|
|
|
Investigators reported a novel derivative of lonidamine, namely HYL001, which selectively and potently inhibited CSCs by targeting mitochondria.
[Pharmacological Research]
|
|
|
|
|
Scientists presented DNA aptamers capable of specific binding to glial tumor cells in vitro, ex vivo, and in vivo for visualization diagnostics of central nervous system tumors.
[Molecular Therapy – Nucleic Acids]
|
|
|
|
|
Harmine was identified as a hit compound based on phenotypic screening of a 2D assay and patient-derived organoid model that was established from a patient with multiple drug resistance and breast metastases.
[Cancer Letters]
|
|
|
|
|
Researchers investigated the molecular and funcitonal makeup of ovarian CSCs (OCSCs) in clinically relevant model systems, and revealed that Matrix Gla Protein was markedly enriched in OCSCs.
[Cell Death & Disease]
|
|
|
|
|
The authors investigated the effects of histone methyltransferases 2, EHMT2 or G9a, on immunosuppressive tumor microenvironment and whether this effect was related to changes on cell stemness.
[CNS Neuroscience & Therapeutics]
|
|
|
|
|
The in vitro and in vivo study demonstrated that tumor necrosis factor-α-induced protein-8-like-2 (TIPE2) sensitized breast cancer cells to paclitaxel by suppressing drug-induced autophagy and CSC properties. [Human Cell]
|
|
|
|
|
|
|
The authors summarize the biological hallmarks and markers of CSCs, and the nanotechnology-based therapies to eradicate them. [Daru-Journal Of Pharmaceutical Sciences]
|
|
|
|
|
|
The FDA outlined plans to move away from single-arm studies and instead favor randomized controlled trials that can potentially serve as the basis for both accelerated and full approval. [Fierce Biotech]
|
|
|
|
|
|
July 24 – 28, 2023 Boston, Massachusetts, United States
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
University of Pennsylvania – Philadelphia, Pennsylvania, United States
|
|
|
|
|
Columbia University – New York City, New York, United States
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
Dana-Farber Cancer Institute – Boston, Massachusetts, United States
|
|
|
|
|